CNS Spectrums最新文献

Transgenerational adverse effects of valproate can't be by-passed. 丙戊酸的跨代副作用是无法回避的。

IF 3.4 3区医学

CNS Spectrums Pub Date : 2025-06-25 DOI: 10.1017/S1092852925000288

Alain Braillon

引用次数: 0

Adolescent cannabis use and onset of bipolar disorder: gaining causal clarity by viewing the evidence through the Bradford Hill lens. 青少年大麻使用和双相情感障碍的发病：通过布拉德福德·希尔透镜观察证据，获得因果关系的清晰度。

IF 3.4 3区医学

CNS Spectrums Pub Date : 2025-06-19 DOI: 10.1017/S1092852925100345

Francesco Bartoli, Daniele Cavaleri, Carlo Bassetti, Marco Broccia, Cristina Crocamo, Gin S Malhi, Giuseppe Carrà

引用次数: 0

Does Compulsory Community Treatment for Discharged Forensic Hospital Patients Work? The Recent Evidence Base. 强制社区治疗对法医院出院病人有效吗？最近的证据库。

IF 3.4 3区医学

CNS Spectrums Pub Date : 2025-06-13 DOI: 10.1017/S1092852925000306

Melinda DiCiro, Melanie Scott

引用次数: 0

Psilocybin and hallucinogenic mushrooms - ERRATUM. 裸盖菇素和致幻蘑菇-勘误。

IF 3.4 3区医学

CNS Spectrums Pub Date : 2025-06-09 DOI: 10.1017/S1092852925100291

Mathieu Fradet, Carlton M Kelly, Anna J Donnelly, Trisha Suppes

引用次数: 0

Glucagon-like Peptide-1 receptor agonists for the prevention and treatment of Parkinson's disease. 胰高血糖素样肽-1受体激动剂预防和治疗帕金森病。

IF 3.4 3区医学

CNS Spectrums Pub Date : 2025-06-09 DOI: 10.1017/S109285292510031X

Serene Lee, Liyang Yin, Naomi Xiao, Taeho Greg Rhee, Heidi K Y Lo, Sabrina Wong, Susan Fox, Kayla Teopiz, Bess Yin-Hung Lam, Yang Jing Zheng, Gia Han Le, Rodrigo B Mansur, Joshua D Rosenblat, Roger S McIntyre

{"title":"Glucagon-like Peptide-1 receptor agonists for the prevention and treatment of Parkinson's disease.","authors":"Serene Lee, Liyang Yin, Naomi Xiao, Taeho Greg Rhee, Heidi K Y Lo, Sabrina Wong, Susan Fox, Kayla Teopiz, Bess Yin-Hung Lam, Yang Jing Zheng, Gia Han Le, Rodrigo B Mansur, Joshua D Rosenblat, Roger S McIntyre","doi":"10.1017/S109285292510031X","DOIUrl":"10.1017/S109285292510031X","url":null,"abstract":"Parkinson's disease (PD) is a severe neurodegenerative disorder characterized by prominent motor and non-motor (e.g., cognitive) abnormalities. Notwithstanding Food and Drug Administration (FDA)-approved treatments (e.g., L-dopa), most persons with PD do not adequately benefit from the FDA-approved treatments and treatment emergent adverse events are often reasons for discontinuation. To date, no current therapy for PD is disease modifying or curative. Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are central nervous system (CNS) penetrant and have shown to be neuroprotective against oxidative stress, neuroinflammation, and insulin resistance, as well as promoting neuroplasticity. Preclinical evidence suggests that GLP-1RAs also attenuate the accumulation of α-synuclein. The cellular and molecular effects of GLP-1RAs provide a basis to hypothesize putative therapeutic benefit in individuals with PD. Extant preclinical and clinical trial evidence in PD provide preliminary evidence of clinically meaningful benefit in the cardinal features of PD. Herein, we synthesize extant preclinical and early-phase clinical evidence, suggesting that GLP-1RAs may be beneficial as a treatment and/or illness progression modification therapeutic in PD.","PeriodicalId":10505,"journal":{"name":"CNS Spectrums","volume":" ","pages":"e44"},"PeriodicalIF":3.4,"publicationDate":"2025-06-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144246798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Response to letter "transgenerational adverse effects of valproate can't be by-passed". 对信函“丙戊酸盐的跨代不良影响无法绕过”的回应。

IF 3.4 3区医学

CNS Spectrums Pub Date : 2025-06-02 DOI: 10.1017/S109285292500029X

Roger S McIntyre

引用次数: 0

A systematic review of anti-suicidal effects of sedative-hypnotics and cognitive behavioral therapy for insomnia. 镇静催眠药和认知行为治疗失眠的抗自杀效果的系统综述。

IF 3.4 3区医学

CNS Spectrums Pub Date : 2025-06-02 DOI: 10.1017/S1092852925000318

Kyle Valentino, Kayla Teopiz, Sabrina Wong, Gia Han Le, Sebastian Badulescu, Danica Johnson, Roger Ho, Taeho Greg Rhee, Bing Cao, Joshua Rosenblat, Rodrigo Mansur, Roger S McIntyre

{"title":"A systematic review of anti-suicidal effects of sedative-hypnotics and cognitive behavioral therapy for insomnia.","authors":"Kyle Valentino, Kayla Teopiz, Sabrina Wong, Gia Han Le, Sebastian Badulescu, Danica Johnson, Roger Ho, Taeho Greg Rhee, Bing Cao, Joshua Rosenblat, Rodrigo Mansur, Roger S McIntyre","doi":"10.1017/S1092852925000318","DOIUrl":"10.1017/S1092852925000318","url":null,"abstract":"Suicide accounts for over 700,000 deaths per year globally and remains a public health priority. Evidence suggests that sleep-related interventions may be effective in reducing depressive symptom severity and suicidal thoughts in patients diagnosed with depression and comorbid insomnia. This study aims to systematically review the efficacy of sedative-hypnotics and/or cognitive behavioral therapy for insomnia (CBT-I) on measures of suicidality.In accordance with Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines, PubMed, Medline, Cochrane Library, Embase, Scopus, and Web of Science were searched from inception to July 30, 2024. Studies were included if they (1) were randomized controlled trials (RCTs) and (2) reported on suicide-related measures associated with sleep interventions as a primary outcome, secondary outcome, or a safety measure. We endeavored to define and operationalize suicidality as suicidal ideation (SI), suicide attempts (SA), and suicide completion (SC). In cases where study authors failed to separate these three dimensions, the term \"suicidality\" was applied.Eighteen studies were identified meeting inclusion criteria, comprised of studies investigating benzodiazepines (n = 2), Z-drugs (n=4), orexin receptor antagonists (ORAs) (n=8), and CBT-I (n=4). Zolpidem reduces SI as well as insomnia (linear association = 0.12, p<0.05) as evidenced by improvement on both the Columbia-Suicide Severity Rating Scale (C-SSRS) and the Scale for Suicide Ideation (SSI). ORAs were not associated with either an increase or decrease in suicidality. CBT-I alleviates SI in patients with insomnia (t = -3.35, p<0.05).Effectively treating insomnia is associated with reduced SI. Available evidence suggests that Food and Drug Administration (FDA)-approved sedative-hypnotics do not increase the risk of suicidality.","PeriodicalId":10505,"journal":{"name":"CNS Spectrums","volume":" ","pages":"e45"},"PeriodicalIF":3.4,"publicationDate":"2025-06-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144198443","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Should Glutamatergic Modulators Be Considered Preferential Treatments for Adults with Major Depressive Disorder and A Reported History of Trauma? Conceptual and Clinical Implications. 谷氨酸调节剂应该被认为是成人重度抑郁症和创伤史患者的优先治疗药物吗？概念和临床意义。

IF 3.4 3区医学

CNS Spectrums Pub Date : 2025-05-26 DOI: 10.1017/S1092852925100278

Kayla Teopiz, Heidi K Y Lo, Moiz Lakhani, Angela Kwan, Poh Khuen Lim, Melanie Zhang, Sabrina Wong, Gia Han Le, Jennifer Swainson, Bing Cao, Christine Dri, Roger Ho, Kyle Valentino, Roger S McIntyre

引用次数: 0

Exploring the potential benefits of clonidine for anxiety disorders. 探索可乐定对焦虑症的潜在益处。

IF 3.4 3区医学

CNS Spectrums Pub Date : 2025-05-16 DOI: 10.1017/S1092852925100266

Esha Aneja B S, Soojae Hollowell, Thomas Schwartz

{"title":"Exploring the potential benefits of clonidine for anxiety disorders.","authors":"Esha Aneja B S, Soojae Hollowell, Thomas Schwartz","doi":"10.1017/S1092852925100266","DOIUrl":"10.1017/S1092852925100266","url":null,"abstract":"Anxiety disorders, characterized by excessive fear and behavioral disturbances, are among the most prevalent psychiatric conditions, yet treatment options remain suboptimal for many patients. Clonidine, an alpha-2 adrenergic receptor agonist, has shown potential anxiolytic effects and may address treatment-resistant cases. This review explores the efficacy, safety, and mechanism of clonidine as a pharmacological option for anxiety disorders, with emphasis on its role in modulating noradrenergic dysfunction and its potential synergistic effects with existing therapies. A literature review was conducted to evaluate clinical studies, case reports, and comparative trials on clonidine's use in anxiety disorders, focusing on its pharmacological profile, efficacy, and tolerability. Evidence suggests clonidine may reduce anxiety symptoms, particularly in treatment-resistant cases and specific populations, such as pediatric patients and those with comorbid psychiatric disorders. Its mechanism involves modulating norepinephrine release and glutamatergic pathways. Case studies and small trials highlight its potential in reducing cognitive symptoms of anxiety, but inconsistencies in efficacy and side effects, including sedation and hypotension, were noted. Comparative studies suggest clonidine may have similar efficacy to SSRIs in some cases but lack large-scale validation. Clonidine presents as a promising pharmacotherapeutic option for anxiety disorders, particularly in cases resistant to conventional treatments or in patients with contraindications to other typical medications. Its mechanism of action, tolerability, and potential synergistic effects with existing therapies underscore the need for continued exploration and clinical trials to establish its optimal role in anxiety disorder management.","PeriodicalId":10505,"journal":{"name":"CNS Spectrums","volume":" ","pages":"e43"},"PeriodicalIF":3.4,"publicationDate":"2025-05-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144076452","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

An exploration of the determinants of risk formulation, care plan and disposition among older adults in the Ontario forensic psychiatry system: implication for practice. 安大略省法医精神病学系统中老年人风险制定、护理计划和处置决定因素的探索：实践意义。

IF 3.4 3区医学

CNS Spectrums Pub Date : 2025-05-15 DOI: 10.1017/S1092852925100242

Mark M Kaggwa, Joan Abaatyo, Arianna Davids, Angela Li, Rebecca Marsh, Precious Agboinghale, John M W Bradford, Gary A Chaimowitz, Andrew T Olagunju

{"title":"An exploration of the determinants of risk formulation, care plan and disposition among older adults in the Ontario forensic psychiatry system: implication for practice.","authors":"Mark M Kaggwa, Joan Abaatyo, Arianna Davids, Angela Li, Rebecca Marsh, Precious Agboinghale, John M W Bradford, Gary A Chaimowitz, Andrew T Olagunju","doi":"10.1017/S1092852925100242","DOIUrl":"10.1017/S1092852925100242","url":null,"abstract":"Background: Advances in medicine have led to an improvement in life expectancy, thus increasing the population of older individuals within the criminal justice system. This study investigates the determinants of risk formulation, care plan, and disposition among older adult forensic patients (OAFP) in Ontario, Canada.Methods: This retrospective analysis utilized the Ontario Review Board database, focusing on 161 OAFP, aged 55 years and older. Hierarchical regression was used to analyze the relationship between changes in risk and six blocks of variables: sociodemographic characteristics (Block 1), circumstances during the index offense (Block 2), current clinical profile (Block 3), past psychiatric history and behavioral patterns (Block 4), criminal history and legal status (Block 5), and recent violent events (Block 6).Results: The median age of patients was 61 years (IQR 58-67), with 83.4% being male. Schizophrenia was the most common diagnosis (68.3%), and 9.3% had neurocognitive disorders. The model with six blocks of factors explained 92% of the variability in risk change. Models 2 (blocks 1 and 2) and 4 (blocks 1-4) were statistically significant, explaining 34% (p = 0.010) and 22% (p = 0.018) of the variance in the change in risk of threat to public safety, respectively. OAFP with a significant risk to public safety were more likely to be inpatients and less likely intoxicated during their index offense.Conclusion: Resources, policies, and a supervised model of care to curtail behavioral risks are relevant to the care of OAFP. Innovative risk management models for OAFP are indicated.","PeriodicalId":10505,"journal":{"name":"CNS Spectrums","volume":" ","pages":"e40"},"PeriodicalIF":3.4,"publicationDate":"2025-05-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144076451","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0